These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 32432713)

  • 1. Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.
    Jemal A; Culp MB; Ma J; Islami F; Fedewa SA
    J Natl Cancer Inst; 2021 Jan; 113(1):64-71. PubMed ID: 32432713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
    Jemal A; Fedewa SA; Ma J; Siegel R; Lin CC; Brawley O; Ward EM
    JAMA; 2015 Nov; 314(19):2054-61. PubMed ID: 26575061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013.
    Houston KA; King J; Li J; Jemal A
    J Urol; 2018 Mar; 199(3):676-682. PubMed ID: 28965781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.
    Butler SS; Muralidhar V; Zhao SG; Sanford NN; Franco I; Fullerton ZH; Chavez J; D'Amico AV; Feng FY; Rebbeck TR; Nguyen PL; Mahal BA
    Cancer; 2020 Feb; 126(4):717-724. PubMed ID: 31794057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variations in Age-Adjusted Prostate Cancer Incidence Rates by Race and Ethnicity After Changes in Prostate-Specific Antigen Screening Recommendation.
    Lai SM; Keighley J; Garimella S; Enko M; Parker WP
    JAMA Netw Open; 2022 Nov; 5(11):e2240657. PubMed ID: 36342715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015.
    Dall'Era MA; deVere-White R; Rodriguez D; Cress R
    Eur Urol Focus; 2019 Nov; 5(6):1014-1021. PubMed ID: 29735368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017.
    Cao Y; Zhang W; Li Y; Fu J; Li H; Li X; Gao X; Zhang K; Liu S
    Prostate; 2021 Oct; 81(14):1071-1077. PubMed ID: 34320230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
    Negoita S; Feuer EJ; Mariotto A; Cronin KA; Petkov VI; Hussey SK; Benard V; Henley SJ; Anderson RN; Fedewa S; Sherman RL; Kohler BA; Dearmon BJ; Lake AJ; Ma J; Richardson LC; Jemal A; Penberthy L
    Cancer; 2018 Jul; 124(13):2801-2814. PubMed ID: 29786851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen testing after the US Preventive Services Task Force recommendation: a population-based analysis of electronic health data.
    Frendl DM; Epstein MM; Fouayzi H; Krajenta R; Rybicki BA; Sokoloff MH
    Cancer Causes Control; 2020 Sep; 31(9):861-867. PubMed ID: 32556947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
    Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
    Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
    Kelly SP; Anderson WF; Rosenberg PS; Cook MB
    Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.
    Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC
    JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
    Drazer MW; Huo D; Eggener SE
    J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
    Zargar H; van den Bergh R; Moon D; Lawrentschuk N; Costello A; Murphy D
    BJU Int; 2017 Jan; 119(1):110-115. PubMed ID: 27454454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.
    Fleshner K; Carlsson SV; Roobol MJ
    Nat Rev Urol; 2017 Jan; 14(1):26-37. PubMed ID: 27995937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State-by-state Variation in Prostate-specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update.
    Vetterlein MW; Dalela D; Sammon JD; Karabon P; Sood A; Jindal T; Meyer CP; Löppenberg B; Sun M; Trinh QD; Menon M; Abdollah F
    Urology; 2018 Feb; 112():56-65. PubMed ID: 29056579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in Prostate-Specific Antigen Screening Since the Implementation of the 2012 US Preventive Services Task Force Recommendations.
    Rahbar H; Karabon P; Menon M; Trinh QD; Abdollah F
    Eur Urol Focus; 2018 Dec; 4(6):1002-1004. PubMed ID: 28753856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations.
    Li J; Berkowitz Z; Hall IJ
    J Am Board Fam Med; 2015; 28(4):491-3. PubMed ID: 26152440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in Incidence of Metastatic Prostate Cancer in the US.
    Desai MM; Cacciamani GE; Gill K; Zhang J; Liu L; Abreu A; Gill IS
    JAMA Netw Open; 2022 Mar; 5(3):e222246. PubMed ID: 35285916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016).
    Schmanke K; Okut H; Ablah E
    Urology; 2021 Mar; 149():110-116. PubMed ID: 33227304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.